Increased risk of cancer in patients with fumarate hydratase germline mutation
- PMID: 16155190
- PMCID: PMC2564537
- DOI: 10.1136/jmg.2005.036400
Increased risk of cancer in patients with fumarate hydratase germline mutation
Abstract
Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a tumour predisposition syndrome caused by heterozygous germline mutations in the fumarate hydratase (FH) gene. The condition is characterised by predisposition to benign leiomyomas of the skin and the uterus, renal cell carcinoma (RCC), and uterine leiomyosarcoma (ULMS). To comprehensively examine the cancer risk and tumour spectrum in Finnish FH mutation positive families, genealogical and cancer data were obtained from 868 individuals. The cohort analysis of the standardised incidence ratios (SIR) was analysed from 256 individuals. FH mutation status was analysed from all available individuals (n = 98). To study tumour spectrum in FH mutation carriers, loss of the wild type allele was analysed from all available tumours (n = 22). The SIR was 6.5 for RCC and 71 for ULMS. The overall cancer risk was statistically significantly increased in the age group of 15-29 years, consistent with features of cancer predisposition families in general. FH germline mutation was found in 55% of studied individuals. Most RCC and ULMS tumours displayed biallelic inactivation of FH, as did breast and bladder cancers. In addition, several benign tumours including atypical uterine leiomyomas, kidney cysts, and adrenal gland adenomas were observed. The present study confirms with calculated risk ratios the association of early onset RCC and ULMS with FH germline mutations in Finns. Some evidence for association of breast and bladder carcinoma with HLRCC was obtained. The data enlighten the organ specific malignant potential of HLRCC.
Conflict of interest statement
Competing interests: there are no competing interests
Similar articles
-
Hereditary leiomyomatosis and renal cell cancer in families referred for fumarate hydratase germline mutation analysis.Clin Genet. 2011 Jan;79(1):49-59. doi: 10.1111/j.1399-0004.2010.01486.x. Clin Genet. 2011. PMID: 20618355
-
No evidence for a genetic modifier for renal cell cancer risk in HLRCC syndrome.Fam Cancer. 2010 Jun;9(2):245-51. doi: 10.1007/s10689-009-9312-2. Fam Cancer. 2010. PMID: 20091131
-
Morphologic and molecular characteristics of uterine leiomyomas in hereditary leiomyomatosis and renal cancer (HLRCC) syndrome.Am J Surg Pathol. 2013 Jan;37(1):74-80. doi: 10.1097/PAS.0b013e31825ec16f. Am J Surg Pathol. 2013. PMID: 23211287 Free PMC article.
-
Renal cell carcinoma in young FH mutation carriers: case series and review of the literature.Fam Cancer. 2020 Jan;19(1):55-63. doi: 10.1007/s10689-019-00155-3. Fam Cancer. 2020. PMID: 31792767 Free PMC article. Review.
-
Fumarate hydratase as a therapeutic target in renal cancer.Expert Opin Ther Targets. 2020 Sep;24(9):923-936. doi: 10.1080/14728222.2020.1804862. Epub 2020 Oct 6. Expert Opin Ther Targets. 2020. PMID: 32744123 Review.
Cited by
-
Aerobic glycolysis: a novel target in kidney cancer.Expert Rev Anticancer Ther. 2013 Jun;13(6):711-9. doi: 10.1586/era.13.57. Expert Rev Anticancer Ther. 2013. PMID: 23773105 Free PMC article. Review.
-
10 rare tumors that warrant a genetics referral.Fam Cancer. 2013 Mar;12(1):1-18. doi: 10.1007/s10689-012-9584-9. Fam Cancer. 2013. PMID: 23377869 Review.
-
cAMP/PKA signaling defects in tumors: genetics and tissue-specific pluripotential cell-derived lesions in human and mouse.Mol Cell Endocrinol. 2013 May 22;371(1-2):208-20. doi: 10.1016/j.mce.2013.01.015. Epub 2013 Feb 26. Mol Cell Endocrinol. 2013. PMID: 23485729 Free PMC article. Review.
-
Oncometabolites in renal cancer.Nat Rev Nephrol. 2020 Mar;16(3):156-172. doi: 10.1038/s41581-019-0210-z. Epub 2019 Oct 21. Nat Rev Nephrol. 2020. PMID: 31636445 Free PMC article. Review.
-
Hereditary Leiomyomatosis and Renal Cell Cancer.Acta Derm Venereol. 2020 Jan 7;100(1):adv00012. doi: 10.2340/00015555-3366. Acta Derm Venereol. 2020. PMID: 31663596 Free PMC article.
References
-
- Tomlinson I P, Alam N A, Rowan A J, Barclay E, Jaeger E E, Kelsell D, Leigh I, Gorman P, Lamlum H, Rahman S, Roylance R R, Olpin S, Bevan S, Barker K, Hearle N, Houlston R S, Kiuru M, Lehtonen R, Karhu A, Vilkki S, Laiho P, Eklund C, Vierimaa O, Aittomaki K, Hietala M, Sistonen P, Paetau A, Salovaara R, Herva R, Launonen V, Aaltonen L A, Multiple Leiomyoma Consortium Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 200230406–410. - PubMed
-
- Kiuru M, Lehtonen R, Arola J, Salovaara R, Jarvinen H, Aittomaki K, Sjoberg J, Visakorpi T, Knuutila S, Isola J, Delahunt B, Herva R, Launonen V, Karhu A, Aaltonen L A. Few FH mutations in sporadic counterparts of tumor types observed in hereditary leiomyomatosis and renal cell cancer families. Cancer Res 2002624554–4557. - PubMed
-
- Alam N A, Rowan A J, Wortham N C, Pollard P J, Mitchell M, Tyrer J P, Barclay E, Calonje E, Manek S, Adams S J, Bowers P W, Burrows N P, Charles‐Holmes R, Cook L J, Daly B M, Ford G P, Fuller L C, Hadfield‐Jones S E, Hardwick N, Highet A S, Keefe M, MacDonald‐Hull S P, Potts E D, Crone M, Wilkinson S, Camacho‐Martinez F, Jablonska S, Ratnavel R, MacDonald A, Mann R J, Grice K, Guillet G, Lewis‐Jones M S, McGrath H, Seukeran D C, Morrison P J, Fleming S, Rahman S, Kelsell D, Leigh I, Olpin S, Tomlinson I P. Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency. Hum Mol Genet 2003121241–1252. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous